for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
PharmAsia News
   Journal TOC RSS feeds Export to Zotero Follow    
   Full-text available via subscription Subscription journal
     ISSN (Print) 1875-7774
     Published by Informa plc Homepage  [13 journals]
  • Kalon Stake Gives Fujifilm Ebola Vaccine Capacity
    • Abstract: A Fujifilm Holdings Corp. subsidiary is to acquire a major stake in a private U.S. contract vaccine manufacturing firm, expanding the Japanese group's interests in the growing biologics production field and providing it with new capabilities for Ebola vaccines if needed.
      PubDate: Mon, 27 Oct 2014 03:30:01 -040
       
  • Novartis Sells Influenza Vaccine Unit To Australia’s CSL For $275
           Million
    • Abstract: Novartis sells its influenza vaccines unit to Australia’s CSL, creating the world’s No. 2 player in the segment.
      PubDate: Sun, 26 Oct 2014 19:40:00 -040
       
  • Progress And Opportunities In Asian Clinical Trials
    • Abstract: The incidence of the five main types of cancer in Asia is expected to surge and multinational and non-industry sponsors alike are increasing the number of clinical trials they conduct in the region, particularly of targeted drugs. A new analysis identifies major trends and opportunities.
      PubDate: Sun, 26 Oct 2014 18:45:01 -040
       
  • SGK Reimbursement Policies Ire Turkish Devices Industry
    • Abstract: The public reimbursement agency SGK’s new pricing policies for medical devices, launched in October, caused severe reactions from the industry, who complained that reimbursement limits for many products were cut back, rendering commercial import and production of these items very difficult.
      PubDate: Sun, 26 Oct 2014 18:40:02 -040
       
  • WuXi Ramps Up Genomics Offering In China Via Foundation Medicine Deal
    • Abstract: WuXi PharmaTech signs a deal with Foundation Medicine to offer a cancer genomics decoding service to customers in China, part of plans announced earlier this year to expand services to innovators.
      PubDate: Sun, 26 Oct 2014 18:40:00 -040
       
  • OncoTherapy Surges On TOPK Inhibitor Promise
    • Abstract: Shares in OncoTherapy Sciences (OTS) surged in Tokyo on Oct. 24 after the Japanese bioventure published promising early findings with a novel anticancer small molecule, OTS964.
      PubDate: Fri, 24 Oct 2014 02:50:01 -040
       
  • Takeda, Sucampo Make Amitiza Deal Global
    • Abstract: Sucampo Pharmaceuticals will get $14 million up front and could earn up to $35 million in milestone fees based on certain sales targets in exchange for giving Takeda Pharmaceutical global rights to the constipation drug Amitiza, versus the partners' prior agreement.
      PubDate: Thu, 23 Oct 2014 22:05:00 -040
       
  • What Slowdown' Sales Rep Demand Robust In China
    • Abstract: A college degree used to be the door-opener for many Chinese graduates to start selling drugs for multinational pharma companies. Demand remains strong, but the bar is rising, and some notable changes will shape the industry for years to come, industry observers say.
      PubDate: Thu, 23 Oct 2014 21:25:01 -040
       
  • Emerging Markets Earnings: GSK CEO Witty Opens Up On China
    • Abstract: GlaxoSmithKline’s CEO Andrew Witty opens up on emerging markets and China after some sly prompting from an analyst broke down what has been a hard stone wall.
      PubDate: Thu, 23 Oct 2014 21:20:00 -040
       
  • Xtandi Japan Label Change Worth $45m To Medivation
    • Abstract: What’s the worth of words? Forty-five million dollars if you are Medivation, which will benefit from a milestone payment of that amount from partner Astellas Pharma in relation to a Japanese labeling change for prostate cancer drug Xtandi (enzalutamide).
      PubDate: Wed, 22 Oct 2014 23:40:03 -040
       
  • India Brandishes Study Discrediting U.S. IP Index
    • Abstract: A new study by academia, at the behest of leading Indian firms, has, among other observations, found flaws in the United States Chamber of Commerce's Global Intellectual Property Center (GIPC) International IP index.
      PubDate: Wed, 22 Oct 2014 20:05:05 -040
       
  • Conformity Assessment On Way Out For Many Australian Devices
    • Abstract: The Australian government will soon amend its regulations to allow most local medical device manufacturers to rely on conformity assessments by European notified bodies. The change is welcome news for the industry, which has long been pushing for a change to the current scenario under which it is mandatory for products to undergo conformity assessment by the Therapeutic Goods Administration.
      PubDate: Wed, 22 Oct 2014 20:05:00 -040
       
  • Emerging Markets Regulatory Tracker: India (Vol. 4 No. 66)
    • Abstract: India’s drug control organization has set up a group to reform systems to make these more user friendly, and is asking for industry representatives for the Task Force.
      PubDate: Wed, 22 Oct 2014 19:55:02 -040
       
  • First Filing For Taisho/Tokuhon’s S-flurbiprofen
    • Abstract: Taisho Pharmaceutical’s marketing authorization application in Japan for TT-063 is the first globally for a transdermal formulation of S-flurbiprofen for osteoarthritis.
      PubDate: Tue, 21 Oct 2014 23:15:01 -040
       
  • FDA’s Arista To India: What’s Your Everest'
    • Abstract: For the quality-hit Indian drug industry, a senior investigator from the U.S. FDA has driven home a few candid messages – lead by example and clean up.
      PubDate: Tue, 21 Oct 2014 23:10:01 -040
       
  • FDA Sees American Dream For Chinese Class 3 Devices
    • Abstract: As China steps up to substitute imported medical devices with domestic products, the U.S. FDA says that it is also likely to see market entry of made in China high-risk medical devices into the United States, according to the agency’s device representative to Beijing.
      PubDate: Tue, 21 Oct 2014 22:55:03 -040
       
  • Southeast Asia Roundup: Thailand, Vietnam, TPP And Infectious Disease
           Diagnosis
    • Abstract: A key drug firm in Thailand has pushed the government to upgrade regulatory standards, while Vietnam sees a surge cardiovascular disease, nations in the region that are part of the Trans-Pacific Partnership talks reportedly zero in on compulsory licensing and several countries have joined together to develop faster diagnosis of infectious diseases.
      PubDate: Mon, 20 Oct 2014 19:30:03 -040
       
  • Cipla’s Hamied Voices Continued Support For Indian Compulsory
           Licenses
    • Abstract: In the last few months Cipla has made moves to co-operate with global drug makers through product licensing deals, in a clear switch in the way the Indian firm wants to do business. But outspoken chairman Yusuf Hamied, the man who demolished the patent barriers of global drug makers, continues to see reasons for India to use interventions like compulsory licenses to facilitate drug access.
      PubDate: Mon, 20 Oct 2014 19:30:00 -040
       
  • Emerging Markets Earnings Roundup: Roche (Part 2)
    • Abstract: Roche feels the heat still from Tarceva competition in China, but Japan regains luster as sales tax hit dims and diagnostics benefit as governments in emerging markets ramp up health care spending.
      PubDate: Mon, 20 Oct 2014 19:00:03 -040
       
  • New Thinking Needed To Invigorate Japan Pharma Innovation
    • Abstract: If Japan is to invigorate pharma and biotech innovation there will need to be changes to ways of thinking by both investors and research-based ventures, along with closer co-ordination between academia, industry and the government, suggested participants in a panel discussion at the BioJapan meeting in Yokohama.
      PubDate: Mon, 20 Oct 2014 03:35:02 -040
       
  • China Biosimilar Discount Expectations May Deter MNCs
    • Abstract: Payers and physicians in China are eager to embrace biosimilars despite a lack of regulatory and reimbursement avenues, notes a recent study by global contact research organization ICON PLC.
      PubDate: Sun, 19 Oct 2014 19:30:03 -040
       
  • Why Novo May Need To Watch Sanofi’s Indian Sugar Clinics Play
    • Abstract: On Sept. 30 Sanofi India made a seemingly plain announcement: a tie up with the Apollo Hospitals group to collaborate on the expansion of Apollo Sugar Clinics that provide integrated diabetes care programs in India.
      PubDate: Sun, 19 Oct 2014 19:25:01 -040
       
  • Pharma R&D Center Stage As Japan Preps For New Agency
    • Abstract: Japan’s government is gearing up for major changes in how it funds basic pharma and medtech R&D, with a new agency due to be set up next March as part of a broader health care policy initiative approved earlier this year.
      PubDate: Fri, 17 Oct 2014 02:20:02 -040
       
  • Emerging Markets Regulatory Tracker: Australia (Vol. 4 No. 65)
    • Abstract: Australia’s TGA eases rules to market for local medical device makers.
      PubDate: Thu, 16 Oct 2014 20:35:01 -040
       
  • Clinical Trials Approvals Rise In India, But Is It Only In Numbers'
    • Abstract: Data suggests that approvals for clinical trials have accelerated in India over the past year, but the ground reality may be disappointing. CRO executives tell PharmAsia News that sponsors are not keenly participating in India, given restrictive guidelines which are at times impractical to follow.
      PubDate: Thu, 16 Oct 2014 20:25:03 -040
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014